Puzolcabtagene Autoleucel: Pediatric First Approval

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in personalized cancer treatment.
• CAR T-cell therapy involves genetically engineering a patient's T cells to target and destroy cancer cells, such as in B-cell malignancies.
• Puzolcabtagene autoleucel is an innovative autologous CAR T-cell therapy developed for B-cell acute lymphoblastic leukemia (B-ALL) and other B-cell lymphomas.

Purpose of the Study:

• To summarize the developmental milestones of puzolcabtagene autoleucel.
• To highlight the first regulatory approval of puzolcabtagene autoleucel in China.
• To provide an overview of this new CAR T-cell therapy for B-cell malignancies.

Main Methods:

• Development of an autologous, humanized anti-CD19 CAR T-cell product.
• Engineering T cells to express a CAR targeting the CD19 antigen, incorporating a humanized single-chain variable fragment to minimize immunogenicity.
• Clinical evaluation for the treatment of CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia.

Main Results:

• Puzolcabtagene autoleucel received its first regulatory approval in China on November 4, 2025.
• The approval is for the treatment of patients aged 3-21 years with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
• The therapy utilizes direct cytotoxicity, apoptosis induction, and TNF ligand-mediated pathways for cancer cell elimination.

Conclusions:

• Puzolcabtagene autoleucel marks a significant therapeutic option for R/R B-ALL in a specific pediatric and young adult population in China.
• The development of puzolcabtagene autoleucel underscores advancements in CAR T-cell therapy for hematological malignancies.
• This approval signifies a key milestone in the clinical translation of personalized immunotherapy for B-cell cancers.